192 related articles for article (PubMed ID: 11471759)
1. Multiple sclerosis treatment 2001.
Rolak LA
Neurol Clin; 2001 Feb; 19(1):107-18. PubMed ID: 11471759
[TBL] [Abstract][Full Text] [Related]
2. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
3. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
O'Connor P;
Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
[No Abstract] [Full Text] [Related]
4. Newer long-term treatments for multiple sclerosis.
Pryse-Phillips W
Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
[No Abstract] [Full Text] [Related]
5. Immunologic therapy for relapsing-remitting multiple sclerosis.
MacLean HJ; Freedman MS
Curr Neurol Neurosci Rep; 2001 May; 1(3):277-85. PubMed ID: 11898530
[TBL] [Abstract][Full Text] [Related]
6. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?
Noseworthy JH
Clin Neuropharmacol; 2003; 26(1):28-37. PubMed ID: 12567162
[No Abstract] [Full Text] [Related]
7. Immunologic therapy for secondary and primary progressive multiple sclerosis.
Myers LW
Curr Neurol Neurosci Rep; 2001 May; 1(3):286-93. PubMed ID: 11898531
[TBL] [Abstract][Full Text] [Related]
8. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
[TBL] [Abstract][Full Text] [Related]
9. Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies--an update.
Donoghue S; Greenlees C
Expert Opin Investig Drugs; 2000 Jan; 9(1):167-71. PubMed ID: 11060669
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Clegg A; Bryant J; Milne R
Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
[No Abstract] [Full Text] [Related]
11. [New therapeutic agents in the management of multiple sclerosis].
Besson G; Carpentier F
Presse Med; 1998 Dec; 27(39):2032-5. PubMed ID: 9893694
[TBL] [Abstract][Full Text] [Related]
12. Interferon beta-1a in primary progressive multiple sclerosis.
Leary SM; Thompson AJ
J Neurol Sci; 2003 Feb; 206(2):215-6. PubMed ID: 12559514
[TBL] [Abstract][Full Text] [Related]
13. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
Frohman EM; Racke M; van Den Noort S
Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
[No Abstract] [Full Text] [Related]
14. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
15. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S;
Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241
[No Abstract] [Full Text] [Related]
16. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
Rudick RA
Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808
[TBL] [Abstract][Full Text] [Related]
18. Factors leading patients to discontinue multiple sclerosis therapies.
Daugherty KK; Butler JS; Mattingly M; Ryan M
J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
[TBL] [Abstract][Full Text] [Related]
19. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
Kornhuber ME; Zierz S
Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
[No Abstract] [Full Text] [Related]
20. [New therapeutic strategies in multiple sclerosis].
Berger E; Rumbach L
Rev Med Interne; 1999 Aug; 20 Suppl 3():346s-350s. PubMed ID: 10480185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
